给 医 护 专 业 人 员 的 信   Cholinesterase Inhibitors (donepezil-, rivastigmine- and galantamine-containing products) - Assessing the potential risk of QT interval prolongation and torsade de pointes (Letter to Healthcare Professionals) (English only)       附件: Cholinesterase Inhibitors (donepezil-, rivastigmine- and galantamine-containing products) - Assessing the potential risk of QT interval prolongation and torsade de pointes (English only)   Related Information: Singapore: QT prolongation and Torsades de Pointes with donepezil (English only) 上载于 2022-08-31 Canada: Summary Safety Review: Cholinesterase inhibitors (donepezil-, rivastigmi... 上载于 2022-07-20 Donepezil and cardiac conduction disorders (Letter to Healthcare Professionals) ... 上载于 2022-03-01 Australia: Donepezil and cardiac conduction disorders (English only) 上载于 2022-03-01